Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$72.7M
27M shares
52-week range
$2.20 – $11.30
9% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
www.cvrx.comNo one on the platform currently holds CVRX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 19,300 | $182.6K |
No one on the platform has traded CVRX yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $65M | +15.9% | $-1.96 | $-2.11–$-1.81 | — | 6 |
| 2027 | $76M | +16.5% | $-1.90 | $-2.27–$-1.49 | — | 6 |
| 2028 | $96M | +25.6% | $-1.67 | $-2.21–$-1.05 | — | 4 |
| 2029 | $121M | +26.1% | $-1.37 | $-1.45–$-1.31 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.52 | $-0.53 | -1.0% |
| 2026-05-11 | $-0.51 | $-0.50 | +2.0% |
| 2026-02-12 | $-0.42 | $-0.46 | -9.5% |
| 2025-11-05 | $-0.50 | $-0.49 | +2.0% |
| 2025-08-04 | $-0.52 | $-0.57 | -9.6% |
| 2025-05-08 | $-0.56 | $-0.53 | +5.4% |
| 2025-02-04 | $-0.37 | $-0.43 | -16.2% |
| 2024-10-29 | $-0.45 |
| $-0.57 |
| -26.7% |
| $207M |
| — |
| PRQRProQR Therapeutics N.V. | $1.85 | -0.54% | $195M | — |
| QTRXQuanterix Corporation | $2.86 | -2.39% | $135M | — |
Source: Financial Modeling Prep · peers by sector/industry
$CVRX CVRx: Brent Binkowski (Chief Operating Officer) Buys 26,223 Shares @ Average Price of $2.91 (Form 4)
View on StockTwits ↗$CVRX Beautiful bounce off the bottom earlier this week.
View on StockTwits ↗$CVRX Mixed (78%): shares could gain if broader payer coverage raises expected Barostim utilization and revenue, but sales-force strain and uncertainty around converting coverage into procedures could pressure the stock by limiting near-term estimate upgrades and... Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/7e1c9879b0e23ee7?utm_source=stocktwits&utm_medium=story_url
View on StockTwits ↗$CVRX thought this would be green today after that nice rise yesterday. Hopefully it won't fall back to $2.20! The only problem now is that there is nothing to stop it from doing so !
View on StockTwits ↗$CVRX my bet IS 3+ at the end of the week. Hold your shares
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.